Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey. more
Time Frame | CRMD | Sector | S&P500 |
---|---|---|---|
1-Week Return | 2.27% | -2.12% | -3% |
1-Month Return | -20.2% | -3.42% | -0.73% |
3-Month Return | 16.12% | -11.13% | 2.87% |
6-Month Return | 93.45% | -5.74% | 7.17% |
1-Year Return | 146.97% | 3.97% | 25.31% |
3-Year Return | 80.04% | 1.05% | 28.38% |
5-Year Return | 14.88% | 34.37% | 81.89% |
10-Year Return | 19.86% | 97.88% | 183.27% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 283.27K | 239.23K | 190.94K | 65.41K | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":84.45,"profit":true},{"date":"2021-12-31","value":67.41,"profit":true},{"date":"2022-12-31","value":23.09,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 373.23K | 204.85K | 148.94K | 3.73K | 205.56K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":54.88,"profit":true},{"date":"2021-12-31","value":39.9,"profit":true},{"date":"2022-12-31","value":1,"profit":true},{"date":"2023-12-31","value":55.08,"profit":true}] |
Gross Profit | (89.97K) | 34.38K | 42.00K | 61.67K | (205.56K) | [{"date":"2019-12-31","value":-145.88,"profit":false},{"date":"2020-12-31","value":55.75,"profit":true},{"date":"2021-12-31","value":68.1,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-333.3,"profit":false}] |
Gross Margin | (31.76%) | 14.37% | 22.00% | 94.29% | (Infinity%) | [{"date":"2019-12-31","value":-33.68,"profit":false},{"date":"2020-12-31","value":15.24,"profit":true},{"date":"2021-12-31","value":23.33,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 20.92M | 27.26M | 29.48M | 30.69M | 48.96M | [{"date":"2019-12-31","value":42.73,"profit":true},{"date":"2020-12-31","value":55.67,"profit":true},{"date":"2021-12-31","value":60.21,"profit":true},{"date":"2022-12-31","value":62.68,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (21.01M) | (27.22M) | (29.44M) | (30.62M) | (48.96M) | [{"date":"2019-12-31","value":-2100787600,"profit":false},{"date":"2020-12-31","value":-2722075200,"profit":false},{"date":"2021-12-31","value":-2943758500,"profit":false},{"date":"2022-12-31","value":-3062396800,"profit":false},{"date":"2023-12-31","value":-4895778800,"profit":false}] |
Total Non-Operating Income/Expense | (950.80K) | 106.51K | (24.37K) | 636.15K | 5.27M | [{"date":"2019-12-31","value":-18.05,"profit":false},{"date":"2020-12-31","value":2.02,"profit":true},{"date":"2021-12-31","value":-0.46,"profit":false},{"date":"2022-12-31","value":12.08,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (21.49M) | (27.20M) | (29.46M) | (30.29M) | (46.34M) | [{"date":"2019-12-31","value":-2149385200,"profit":false},{"date":"2020-12-31","value":-2719707800,"profit":false},{"date":"2021-12-31","value":-2946041200,"profit":false},{"date":"2022-12-31","value":-3028732200,"profit":false},{"date":"2023-12-31","value":-4633922700,"profit":false}] |
Income Taxes | (5.06M) | (5.17M) | (1.25M) | (585.62K) | (2.00) | [{"date":"2019-12-31","value":-506077800,"profit":false},{"date":"2020-12-31","value":-516939500,"profit":false},{"date":"2021-12-31","value":-125018600,"profit":false},{"date":"2022-12-31","value":-58561700,"profit":false},{"date":"2023-12-31","value":-200,"profit":false}] |
Income After Taxes | (16.43M) | (22.03M) | (28.21M) | (29.70M) | (46.34M) | [{"date":"2019-12-31","value":-1643307400,"profit":false},{"date":"2020-12-31","value":-2202768300,"profit":false},{"date":"2021-12-31","value":-2821022600,"profit":false},{"date":"2022-12-31","value":-2970170500,"profit":false},{"date":"2023-12-31","value":-4633922500,"profit":false}] |
Income From Continuous Operations | (16.43M) | (22.03M) | (28.21M) | (29.70M) | (46.34M) | [{"date":"2019-12-31","value":-1643307400,"profit":false},{"date":"2020-12-31","value":-2202768300,"profit":false},{"date":"2021-12-31","value":-2821022600,"profit":false},{"date":"2022-12-31","value":-2970170500,"profit":false},{"date":"2023-12-31","value":-4633922700,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (16.43M) | (22.03M) | (28.21M) | (29.70M) | (46.34M) | [{"date":"2019-12-31","value":-1643307400,"profit":false},{"date":"2020-12-31","value":-2202768300,"profit":false},{"date":"2021-12-31","value":-2821022600,"profit":false},{"date":"2022-12-31","value":-2970170500,"profit":false},{"date":"2023-12-31","value":-4633922700,"profit":false}] |
EPS (Diluted) | (0.89) | (0.76) | (0.74) | (0.74) | (0.92) | [{"date":"2019-12-31","value":-89,"profit":false},{"date":"2020-12-31","value":-76,"profit":false},{"date":"2021-12-31","value":-74,"profit":false},{"date":"2022-12-31","value":-74,"profit":false},{"date":"2023-12-31","value":-92,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CRMD | |
---|---|
Cash Ratio | 2.49 |
Current Ratio | 3.96 |
Quick Ratio | 3.60 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CRMD | |
---|---|
ROA (LTM) | -37.69% |
ROE (LTM) | -65.04% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CRMD | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.24 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.76 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CRMD | |
---|---|
Trailing PE | NM |
Forward PE | 13.19 |
P/S (TTM) | 42.41 |
P/B | 8.86 |
Price/FCF | NM |
EV/R | 38.70 |
EV/Ebitda | NM |
PEG | NM |
CorMedix Inc (CRMD) share price today is $8.57
Yes, Indians can buy shares of CorMedix Inc (CRMD) on Vested. To buy CorMedix Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CRMD stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of CorMedix Inc (CRMD) via the Vested app. You can start investing in CorMedix Inc (CRMD) with a minimum investment of $1.
You can invest in shares of CorMedix Inc (CRMD) via Vested in three simple steps:
The 52-week high price of CorMedix Inc (CRMD) is $13.85. The 52-week low price of CorMedix Inc (CRMD) is $2.89.
The price-to-earnings (P/E) ratio of CorMedix Inc (CRMD) is
The price-to-book (P/B) ratio of CorMedix Inc (CRMD) is 8.86
The dividend yield of CorMedix Inc (CRMD) is 0.00%
The market capitalization of CorMedix Inc (CRMD) is $492.70M
The stock symbol (or ticker) of CorMedix Inc is CRMD